Semi-finished Vaccine Production Department 2
General Introduction
The Semi-finished Vaccine Production Department 2 was established in 2006, primarily tasked with producing semi-finished Measles vaccine.
In 2013, the department adopted the semi-finished Rubella vaccine production process under the technical support project "Strengthening Measles-Rubella Combined Vaccine Production Capacity."
By 2018, the Measles-Rubella vaccine was officially approved and added to the National EPI.
Functions and Tasks
Currently, the department produces two main vaccines for the EPI and export:
Semi-finished Measles vaccine
Semi-finished Rubella vaccine
- All products are evaluated to meet WHO-GMP quality standards.
- Participate in scientific research and medical biological production at the Center.
Upgrade production capacity
The Japan-transferred Measles vaccine process has a maximum capacity of 7.5 million doses/year. Annually, the department provides about 3 million single Measles doses and 3 million Measles-Rubella doses, meeting domestic demand.
To meet surge demand during outbreaks, since 2017, the department has researched and expanded production scale:
- 2017: Increased Measles vaccine batch size from 140 to 210 bottles.
- Năm 2019: Hoàn thiện quy trình sản xuất vắc xin Sởi bán thành phẩm với kích cỡ 430 chai/lô, nâng công suất lên khoảng 26–30 triệu liều/năm – đủ để hướng tới xuất khẩu trong tương lai.
For Rubella vaccine:
- Trial production began in 2014-2015, with licensing in 2017. In 2020: Completed batch size increase from 140 to 220 bottles, saving costs and increasing yield.
- By 2022, the department had produced about 42 million semi-finished doses, including 16.7 million Measles-Rubella doses for the EPI.
